SFA — Sopharma AD Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedMid CapSuper Stock

Annual income statement for Sopharma AD, fiscal year end - December 31st, BGN millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,616	1,675	1,895	2,153	2,640
Cost of Revenue
Gross Profit	311	324	377	420	509
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,564	1,609	1,800	2,072	2,501
Operating Profit	51.6	66.3	94.8	80.9	139
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	97.6	85.1	111	92.1	157
Provision for Income Taxes
Net Income After Taxes	91.7	76.3	99.9	80.4	142
Minority Interest
Net Income Before Extraordinary Items
Net Income	89.5	71.1	96	76.3	134
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	89.5	71.1	96	76.3	134
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.184	0.253	0.236	0.158	0.673
Dividends per Share